NuVasive, Inc. [NASDAQ:NUVA]: Analyst Rating and Earnings
Stock market traders oftentimes pay a lot of attention to what top analysts say regarding a potential investment. Regarding NuVasive, Inc. [NUVA], the latest average analyst recommendation we can see is from the quarter closing in December. On average, stock market experts give NUVA an Hold rating. Its stock price has been found in the range of 9.76 to 20.02. This is compared to its latest closing price of $56.12.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for NuVasive, Inc. [NUVA] is sitting at 2.53. This is compared to 1 month ago, when its average rating was 2.47.
For the quarter ending in Sep-18 NuVasive, Inc. [NUVA] generated $0.27 billion in sales. That’s 2.21% higher than the average estimate of $0.27 billion as provided by Wall Street analysts. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run.
Pay attention for this company’s financial results, of which the next release is scheduled to happen on Wed 20 Feb (In 8 Days).
Fundamental Analysis of NuVasive, Inc. [NUVA]
Now let’s turn to look at profitability: with a current Operating Margin for NuVasive, Inc. [NUVA] sitting at +11.86 and its Gross Margin at +69.20, this company’s Net Margin is now 2.20%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is 9.02, and its Return on Invested Capital has reached 7.30%. Its Return on Equity is 11.14, and its Return on Assets is 5.17. These metrics suggest that this NuVasive, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, NuVasive, Inc. [NUVA] has generated a Total Debt to Total Equity ratio of 73.29. Similarly, its Total Debt to Total Capital is 42.29, while its Total Debt to Total Assets stands at 35.56. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 73.29, and its Long-Term Debt to Total Capital is 42.29. This company is not leveraging its assets to take on debt, which stunts its growth and limits the ROI for investors.
What about valuation? This company’s Enterprise Value to EBITDA is 12.55 and its Total Debt to EBITDA Value is 2.40. The Enterprise Value to Sales for this firm is now 2.81, and its Total Debt to Enterprise Value stands at 0.16. NuVasive, Inc. [NUVA] has a Price to Book Ratio of 3.76, a Price to Cash Flow Ratio of 18.04 and P/E Ratio of 122.24. These metrics show that this company has a mixed appeal, and ROI could be a gain or a loss.
Shifting the focus to workforce efficiency, NuVasive, Inc. [NUVA] earns $395,969 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 5.56 and its Total Asset Turnover is 0.64. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 1.94 and its Current Ratio is 3.48. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Let’s now turn our attention to trading performance: NuVasive, Inc. [NUVA] has 52.43M shares outstanding, amounting to a total market cap of $2.94B. Its stock price has been found in the range of 43.51 to 72.41. At its current price, it has moved by -23.84% from its 52-week high, and it has moved 26.75% from its 52-week low.
This stock’s Beta value is currently 1.16, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 64.14. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is NuVasive, Inc. [NUVA] a Reliable Buy?
Shares of NuVasive, Inc. [NUVA], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.